Advance one process architecture, scale, facility, campaign or transfer option only after product quality, process robustness, equipment fit, finite resources, economics, environmental inventory and validation evidence remain consistent.
Independent company use-case study · biopharmaceutical CRDMO
WuXi BiologicsFive process decisions
Choose one use case. Add authorised plant data. Test capacity, cost and constraints.
Decision brief
One question. One model.
One authorised mammalian, microbial or other biologics process from cell or strain basis through cultivation, harvest, purification, formulation and relevant drug-product handoff, including cleaning, utilities, quality holds, waste and transfer.
Five practical use cases
Five places to start.
Evaluation scopes for WuXi Biologics—not claims of current software use.Compare complete biologics process architectures
Connect cell or strain development, cultivation, harvest, purification, formulation and drug-product handoff on one material, quality, equipment, time and uncertainty basis.
Screen scale-up, transfer and facility fit
Translate authorised development evidence into mixing, gas-transfer, heat-removal, filtration and chromatography-load envelopes, then test requirements against approved target equipment and utilities.
Test global multiproduct CRDMO campaigns offline
Schedule eligible upstream, downstream, buffer, fill-finish, cleaning, laboratory and release resources without representing WuXi Biologics customers, actual capacity, occupancy or delivery commitments.
Compare process and facility TEA/LCA scenarios
Evaluate intensification, single-use, facility or supply options across yield, materials, energy, water, waste, capital and operating cost under the same functional unit and boundary.
Govern technology-transfer and validation evidence
Link process history, scale assumptions, critical parameters, analytical methods, risks, engineering and GMP runs, deviations and acceptance criteria without performing formal validation.
Action pack
Inputs in. Decisions out.
- Molecule, modality, production system, quality and demand basis
- Growth, titer, recovery, formulation and characterisation evidence
- Equipment eligibility, scale rules, hold times and facility limits
- Materials, consumables, utilities, waste, cost and lifecycle factors
- End-to-end process-architecture comparison
- Scale-up, transfer and facility-fit evidence map
- Finite portfolio schedule and accepted-capacity range
- TEA/LCA screen and validation-readiness register
- Select one customer-authorised process or transfer decision.
- Declare product, quality, facility and transfer boundaries.
- Import development, characterisation and equipment evidence.
Evidence and limits
Public evidence only.
- WuXi Biologics — CompanyOfficial current group context for WuXi Biologics' CRDMO model, geographic footprint and end-to-end services.
- WuXi Biologics — Privacy policyOfficial legal boundary identifying WuXi Biologics Co., Ltd. as a Chinese subsidiary of WuXi Biologics (Cayman) Inc.
- WuXi Biologics — Process development and scale-upOfficial context for upstream and downstream process development, scale-up and manufacturing-readiness services.
- WuXi Biologics — Clinical drug-substance manufacturingOfficial context for technology-transfer workflows, clinical manufacturing, analytical support and company toolboxes.
- WuXi Biologics — SustainabilityOfficial current source for sustainability reports and the company's Green CRDMO and operational environmental context.
- WuXi Biologics — 2025 annual resultsOfficial current legal and operating context for WuXi Biologics (Cayman) Inc. and its research-development-manufacturing capabilities.
Guardrail: No WuXi Biologics group, WuXi XDC or WuXi AppTec customer, molecule, process, platform, site, campaign, capacity, occupancy, yield, cost, environmental result, deployment or digital system is represented. Technology transfer, validation, PPQ, GxP, batch release, regulatory and commercial decisions remain under approved company and customer systems.